Home / ADAMTS13 / Recombinant Human ADAMTS13 (Full Length) Protein, CF

Recombinant Human ADAMTS13 (Full Length) Protein, CF

Catalog #: 6156-AD
8 Citations Datasheet
Catalog # Availability Size / Price Qty
6156-AD-020
R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (8)
FAQs
Supplemental Products
Reviews
Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human ADAMTS13 (Full Length) Protein, CF Summary

Product Specifications

Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<1.0 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to cleave the fluorogenic peptide substrate, FRETS-VWF73. The specific activity is >10 pmol/min/μg, as measured under the described conditions.
Source
Chinese Hamster Ovary cell line, CHO-derived human ADAMTS13 protein
Gln34-Thr1427, with a C-terminal 10-His tag
Accession #
Q76LX8
N-terminal Sequence
Analysis
Ala75, Gln34 inferred from enzymatic pyroglutamate treatment revealing Gln35
Predicted Molecular Mass
147 kDa & 151 kDa
SDS-PAGE
160-180 kDa, reducing conditions

Product Datasheets

You must select a language.

x

6156-AD

Product Datasheet

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

6156-AD

Formulation Supplied as a 0.2 μm filtered solution in HEPES and NaCl.
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Assay Procedure

Materials
  • Assay Buffer: 50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% (w/v) Brij-35, pH 7.5 (TCNB)
  • Recombinant Human ADAMTS13 (rhADAMTS13) Full Length (Catalog # 6156-AD)
  • Substrate: FRETS-VWF73 (AnaSpec, Catalog # 63728), 100 µM stock in DMSO
  • F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
  • Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent
  1. Dilute rhADAMTS13 to 20 µg/mL in Assay Buffer.
  2. Dilute Substrate to 8 µM in Assay Buffer.
  3. Load 50 µL of dilute rhADAMTS13 into a plate, and start the reactions by adding 50 µL of 8 µM Substrate.  Include a Substrate Blank containing 50 µL of Assay Buffer and 50 µL of 8 µM Substrate.
  4. Read at excitation and emission wavelengths of 340 nm and 450 nm (top read), respectively, in kinetic mode for 5 minutes.
  5. Calculate specific activity:

     Specific Activity (pmol/min/µg) =

 Adjusted Vmax* (RFU/min) x Conversion Factor** (pmol/RFU)
amount of enzyme (µg)

*Adjusted for Substrate Blank
**Derived using calibration standard FRETS-25-STD1 (Peptides International, Catalog # STD-3720-V).

Per Well:
  • rhADAMTS13: 1 µg
  • Substrate: 4 µM

Background: ADAMTS13

ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin motifs 13), also known as von Willebrand Factor (vWF) cleaving protease, is a member of the family of secreted zinc proteases with a multidomain structure (1-3). The protein precursors consist of a signal peptide and following domains: pro, catalytic, disintegrin-like, thromobspondin type 1 (TSP1) motif, a cysteine-rich domain, a spacer region, a second set of seven TSP1 repeats, and two CUB domins. The only known substrate of ADAMTS13 is vWF, a blood glycoprotein with two homeostatic functions (4). It is required for platelet adhesion to sites of vascular damage and acts as a carrier protein for blood-clotting factor VIII in the circulation. It exists in plasma as multimers, the largest of which effectively mediate platelet adhesion. ADAMTS13 cleaves multimeric vWF in the A2 domain at the position between Tyr1605 and Met1606. A defect in ADAMTS13 activity is a cause of congenital thrombotic thrombocytopenic purpura (TTP), also known as Upshaw Schulman syndrome. Lack of ADAMTS13 activity allows unusually high concentrations vWF (UlvWF) to accumulate in plasma (5). These UlvWF multimers have a tendency to agglutinate circulating platelets at sites with high levels of shear stress to cause TTP. The recombinant human vWFA2 cleaving activity of recombinant human ADAMTS13 can be inhibited by 5 mM 1,10‑phenanthroline.

References
  1. Furlan, M. et al. (1996) Blood. 87:4223.
  2. Porter, S. et al. (2005) Biochem. J. 386:15.
  3. Chung, D. W. and J.E. Saddler (2004) in Handbook of Proteolytic Enzymes, Barret, A. J. et al. eds. pp. 747.
  4. Wu, J.J. et al. (2006) PNAS. 103:18470.
  5. Levy, G.G. et al. (2005) Blood. 106:11.
Long Name
A Disintegrin-like and Metalloproteinase Domain with Thrombospondin Motifs 13
Entrez Gene IDs
11093 (Human); 279028 (Mouse); 362091 (Rat)
Alternate Names
A disintegrin and metalloproteinase with thrombospondin motifs 13; a disintegrin-like and metalloprotease (reprolysin type) with thrombospondintype 1 motif, 13; ADAM metallopeptidase with thrombospondin type 1 motif, 13; ADAMTS13; ADAM-TS13; ADAMTS-13; DKFZp434C2322; EC 3.4.24.14; EC 3.4.24.82; EC 3.4.24.87; FLJ42993; MGC118899; MGC118900; TTP; TTPADAM-TS 13; vWF-cleaving protease; vWF-CP; vWF-CPC9orf8; VWFCPvon Willebrand factor-cleaving protease

Citations for Recombinant Human ADAMTS13 (Full Length) Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

8 Citations: Showing 1 - 8
Filter your results:

Filter by:

  1. The effect of ADAMTS13 on graft-versus-host disease
    Authors: Li, D;Cho, MS;Gonzalez-Delgado, R;Liang, X;Dong, JF;Cruz, MA;Ma, Q;Afshar-Kharghan, V;
    Journal of cellular and molecular medicine
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  2. Optimization of plasma-based BioID identifies plasminogen as a ligand of ADAMTS13
    Authors: Madarati, H;DeYoung, V;Singh, K;Sparring, T;Kwong, AC;Fredenburgh, JC;Teney, C;Koschinsky, ML;Boffa, MB;Weitz, JI;Kretz, CA;
    Scientific reports
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay
  3. CaMKII orchestrates endoplasmic reticulum stress and apoptosis in doxorubicin-induced cardiotoxicity by regulating the IRE1alpha/XBP1s pathway
    Authors: L Kong, Y Zhang, J Ning, C Xu, Z Wang, J Yang, L Yang
    Journal of Cellular and Molecular Medicine, 2022-09-16;0(0):.
    Species: Mouse
    Sample Types:
    Applications: Bioassay
  4. Distinct impact of IgG subclass on autoantibody pathogenicity in different IgG4-mediated diseases
    Authors: Y Bi, J Su, S Zhou, Y Zhao, Y Zhang, H Zhang, M Liu, A Zhou, J Xu, M Pan, Y Zhao, F Li
    Elife, 2022-08-03;11(0):.
    Species: Mouse
    Sample Types: Cell Culture Supernates
    Applications: ELISA Standard
  5. Optimization of anti-ADAMTS13 antibodies for the treatment of ADAMTS13-related bleeding disorder in patients receiving circulatory assist device support
    Authors: T Ito, T Minamitani, M Hayakawa, R Otsubo, H Akiba, K Tsumoto, M Matsumoto, T Yasui
    Scientific Reports, 2021-11-16;11(1):22341.
    Species: Human
    Sample Types: Protein
    Applications: ELISA Capture, Surface Plasmon Resonance
  6. High throughput protease profiling comprehensively defines active site specificity for thrombin and ADAMTS13
    Authors: CA Kretz, K Tomberg, A Van Esbroe, A Yee, D Ginsburg
    Sci Rep, 2018-02-12;8(1):2788.
    Applications: Bioassay
  7. ADAMTS13 and its variants promote angiogenesis via upregulation of VEGF and VEGFR2.
    Authors: Lee, Manfai, Keener, Justin, Xiao, Juan, Long Zheng, X, Rodgers, George M
    Cell Mol Life Sci, 2014-06-21;72(2):349-56.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  8. Effect of ADAMTS-13 on cerebrovascular microthrombosis and neuronal injury after experimental subarachnoid hemorrhage.
    Authors: Muroi C, Fujioka M, Mishima K, Irie K, Fujimura Y, Nakano T, Fandino J, Keller E, Iwasaki K, Fujiwara M
    J Thromb Haemost, 2014-04-01;12(4):505-14.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs
Loading...

Reviews for Recombinant Human ADAMTS13 (Full Length) Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human ADAMTS13 (Full Length) Protein, CF and earn rewards!

Have you used Recombinant Human ADAMTS13 (Full Length) Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review